^
Association details:
| Biomarker: | MET exon 14 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | glesatinib (MGCD265) (VEGFR inhibitor, c-MET inhibitor, AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
Published date:
12/02/2022
Excerpt:
Antitumor activity was observed with glesatinib FBS 1050 mg twice daily and SDD 750 mg twice daily in tumors harboring MET/AXL alteration or aberrant protein expression, particularly in patients with non--small cell lung cancer (NSCLC). In patients with NSCLC, the objective response rate was 25.9% in those with MET/AXL mutation or amplification and 30.0% in a subset with MET-activating mutations. All six partial responses occurred in patients with tumors carrying MET exon 14 deletion mutations.
DOI:
10.1007/s11523-022-00931-9
Trial ID:
